Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779-781)

Thrombosis and Haemostasis

Volumn 100, Issue 1, 2008, Pages 168-169

  Schindewolf, Marc ^a   Lindhoff Last, Edelgard ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; DANAPAROID; DERMATAN SULFATE; FONDAPARINUX; HEPARAN SULFATE; HEPARIN;

DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LETTER; PRIORITY JOURNAL; SULFATION; THROMBOCYTOPENIA; THROMBOSIS;

ANTIBODIES; ANTICOAGULANTS; HEPARIN; HUMANS; PLATELET COUNT; PLATELET FACTOR 4; POLYSACCHARIDES; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 46749126934     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-04-0222     Document Type: Letter

References (15)

1. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. New Engl J Med 2006; 355: 809-817.
2. Greinacher A, Eichler P, Lubenow N, et al. Drug-induced and drug-dependent immune thrombocytopenias. Rev Clin Exp Hematol. 2001; 5: 166-200.
3. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 757-758.
4. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007; 82: 1037-1043.
5. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-3796.
6. Pouplard C, Couvret C, Regina S, et al. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 2005; 3: 2813-2815.
7. Lindhoff-Last E, Gerdsen F, Ackermann H, et al. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113: 886-890.
8. Schwarzinger I, Speiser W, Lubenow N, et al. Heparin-platelet factor (PF) 4 antibodies in patients with pseudothrombocytopenia: coincidence or association? Thromb Haemost 2000; 84: 1123-1124.
9. Alpert D, Mandl LA, Erkan D, et al. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis 2008; 67: 395-401.
10. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95: 967-981.
11. Schindewolf M, Mosch G, Bauersachs RM, et al. Safe anticoagulation with danaparoid in pregnancy and lactation. Thromb Haemost 2004; 92: 211.
12. Greinacher A, Alban S, Dummel V, et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 886-892.
13. Schindewolf M, Luxembourg B, Lindhoff-Last E. Use of fondaparinux in patients with heparin-induced thrombocytopenia type II. Vasa 2006; 35: 70 Abstract.
14. Lobo B, Finch C, Howard A, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208-214.
15. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 2006; 40: 1383-1387.